跳轉至內容
Merck
全部照片(1)

文件

1279000

USP

氟脲嘧啶

United States Pharmacopeia (USP) Reference Standard

同義詞:

5-氟脲嘧啶, 2,4-二羟基-5-氟嘧啶, 5-FU, 5-氟-2,4(1H,3H)-嘧啶二酮

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C4H3FN2O2
CAS號碼:
分子量::
130.08
Beilstein:
127172
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

fluorouracil

製造商/商標名

USP

mp

282-286 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

InChI 密鑰

GHASVSINZRGABV-UHFFFAOYSA-N

基因資訊

human ... TYMS(7298)

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Fluorouracil USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Flucytosine
  • Flucytosine Capsules
  • Fluorouracil
  • Fluorouracil Cream
  • Fluorouracil Injection
  • Fluorouracil Topical Solution

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

產品號碼
描述
訂價

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral - Carc. 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 2

1 of 2

Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
S López-Estévez et al.
Gene therapy, 21(7), 673-681 (2014-05-09)
Suicide gene therapy (SGT) is a promising strategy for treating cancer. In this work, we show that thymidine phosphorylase (TP) deficiency, the underlying genetic defect in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), presents an opportunity to apply SGT using capecitabine, a commonly
Zhe Guo et al.
Annals of surgical oncology, 21(9), 3069-3076 (2014-04-15)
It is unclear whether hepatic resection (HR) or transarterial chemoembolization (TACE) is associated with better outcomes for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A. The present study compared survival for patients with BCLC stage
John M L Ebos et al.
EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and
Steven R Alberts et al.
PharmacoEconomics, 32(12), 1231-1243 (2014-08-27)
Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering medical costs for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients. This study assessed the validity of those findings

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務